HYAL1 hyaluronidase in prostate cancer: A tumor promoter and suppressor

Vinata B. Lokeshwar, Wolfgang H. Cerwinka, Tadahiro Isoyama, Bal L. Lokeshwar

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

Hyaluronidases degrade hyaluronic acid, which promotes metastasis. HYAL1 type hyaluronidase is an independent prognostic indicator of prostate cancer progression and a biomarker for bladder cancer. However, it is controversial whether hyaluronidase (e.g., HYAL1) functions as a tumor promoter or as a suppressor. We stably transfected prostate cancer cells, DU145 and PC-3 ML, with HYAL1-sense (HYAL1-S), HYAL1-antisense (HYAL1-AS), or vector DNA. HYAL1-AS transfectants were not generated for PC-3 ML because it expresses little HYAL1. HYAL1-S transfectants produced ≤42 milliunits (moderate overproducers) or ≥80 milliunits hyaluronidase activity (high producers). HYAL1-AS transfectants produced <10% hyaluronidase activity when compared with vector transfectants (18-24 milliunits). Both blocking HYAL1 expression and high HYAL1 production resulted in a 4- to 5-fold decrease in prostate cancer cell proliferation. HYAL1-AS transfectants had a G2-M block due to decreased cyclin B1, cdc25c, and cdc2/p34 expression and cdc2/p34 kinase activity. High HYAL1 producers had a 3-fold increase in apoptotic activity and mitochondrial depolarization when compared with vector transfectants and expressed activated proapoptotic protein WOX1. Blocking HYAL1 expression inhibited tumor growth by 4- to 7-fold, whereas high HYAL1 producing transfectants either did not form tumors (DU145) or grew 3.5-fold slower (PC-3 ML). Whereas vector and moderate HYAL1 producers generated muscle and blood vessel infiltrating tumors, HYAL1-AS tumors were benign and contained smaller capillaries. Specimens of high HYAL1 producers were 99% free of tumor cells. This study shows that, depending on the concentration, HYAL1 functions as a tumor promoter and as a suppressor and provides a basis for anti-hyaluronidase and high-hyaluronidase treatments for cancer.

Original languageEnglish (US)
Pages (from-to)7782-7789
Number of pages8
JournalCancer Research
Volume65
Issue number17
DOIs
StatePublished - Sep 1 2005

Fingerprint

Hyaluronoglucosaminidase
Carcinogens
Prostatic Neoplasms
Neoplasms
Vascular Tissue Neoplasms
Cyclin B1
Hyaluronic Acid
Urinary Bladder Neoplasms
Phosphotransferases
Biomarkers
Cell Proliferation
Neoplasm Metastasis
Muscles
DNA
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

HYAL1 hyaluronidase in prostate cancer : A tumor promoter and suppressor. / Lokeshwar, Vinata B.; Cerwinka, Wolfgang H.; Isoyama, Tadahiro; Lokeshwar, Bal L.

In: Cancer Research, Vol. 65, No. 17, 01.09.2005, p. 7782-7789.

Research output: Contribution to journalArticle

Lokeshwar, Vinata B. ; Cerwinka, Wolfgang H. ; Isoyama, Tadahiro ; Lokeshwar, Bal L. / HYAL1 hyaluronidase in prostate cancer : A tumor promoter and suppressor. In: Cancer Research. 2005 ; Vol. 65, No. 17. pp. 7782-7789.
@article{4a7c11b57cc146b18c00c1f5c7001613,
title = "HYAL1 hyaluronidase in prostate cancer: A tumor promoter and suppressor",
abstract = "Hyaluronidases degrade hyaluronic acid, which promotes metastasis. HYAL1 type hyaluronidase is an independent prognostic indicator of prostate cancer progression and a biomarker for bladder cancer. However, it is controversial whether hyaluronidase (e.g., HYAL1) functions as a tumor promoter or as a suppressor. We stably transfected prostate cancer cells, DU145 and PC-3 ML, with HYAL1-sense (HYAL1-S), HYAL1-antisense (HYAL1-AS), or vector DNA. HYAL1-AS transfectants were not generated for PC-3 ML because it expresses little HYAL1. HYAL1-S transfectants produced ≤42 milliunits (moderate overproducers) or ≥80 milliunits hyaluronidase activity (high producers). HYAL1-AS transfectants produced <10{\%} hyaluronidase activity when compared with vector transfectants (18-24 milliunits). Both blocking HYAL1 expression and high HYAL1 production resulted in a 4- to 5-fold decrease in prostate cancer cell proliferation. HYAL1-AS transfectants had a G2-M block due to decreased cyclin B1, cdc25c, and cdc2/p34 expression and cdc2/p34 kinase activity. High HYAL1 producers had a 3-fold increase in apoptotic activity and mitochondrial depolarization when compared with vector transfectants and expressed activated proapoptotic protein WOX1. Blocking HYAL1 expression inhibited tumor growth by 4- to 7-fold, whereas high HYAL1 producing transfectants either did not form tumors (DU145) or grew 3.5-fold slower (PC-3 ML). Whereas vector and moderate HYAL1 producers generated muscle and blood vessel infiltrating tumors, HYAL1-AS tumors were benign and contained smaller capillaries. Specimens of high HYAL1 producers were 99{\%} free of tumor cells. This study shows that, depending on the concentration, HYAL1 functions as a tumor promoter and as a suppressor and provides a basis for anti-hyaluronidase and high-hyaluronidase treatments for cancer.",
author = "Lokeshwar, {Vinata B.} and Cerwinka, {Wolfgang H.} and Tadahiro Isoyama and Lokeshwar, {Bal L.}",
year = "2005",
month = "9",
day = "1",
doi = "10.1158/0008-5472.CAN-05-1022",
language = "English (US)",
volume = "65",
pages = "7782--7789",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - HYAL1 hyaluronidase in prostate cancer

T2 - A tumor promoter and suppressor

AU - Lokeshwar, Vinata B.

AU - Cerwinka, Wolfgang H.

AU - Isoyama, Tadahiro

AU - Lokeshwar, Bal L.

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Hyaluronidases degrade hyaluronic acid, which promotes metastasis. HYAL1 type hyaluronidase is an independent prognostic indicator of prostate cancer progression and a biomarker for bladder cancer. However, it is controversial whether hyaluronidase (e.g., HYAL1) functions as a tumor promoter or as a suppressor. We stably transfected prostate cancer cells, DU145 and PC-3 ML, with HYAL1-sense (HYAL1-S), HYAL1-antisense (HYAL1-AS), or vector DNA. HYAL1-AS transfectants were not generated for PC-3 ML because it expresses little HYAL1. HYAL1-S transfectants produced ≤42 milliunits (moderate overproducers) or ≥80 milliunits hyaluronidase activity (high producers). HYAL1-AS transfectants produced <10% hyaluronidase activity when compared with vector transfectants (18-24 milliunits). Both blocking HYAL1 expression and high HYAL1 production resulted in a 4- to 5-fold decrease in prostate cancer cell proliferation. HYAL1-AS transfectants had a G2-M block due to decreased cyclin B1, cdc25c, and cdc2/p34 expression and cdc2/p34 kinase activity. High HYAL1 producers had a 3-fold increase in apoptotic activity and mitochondrial depolarization when compared with vector transfectants and expressed activated proapoptotic protein WOX1. Blocking HYAL1 expression inhibited tumor growth by 4- to 7-fold, whereas high HYAL1 producing transfectants either did not form tumors (DU145) or grew 3.5-fold slower (PC-3 ML). Whereas vector and moderate HYAL1 producers generated muscle and blood vessel infiltrating tumors, HYAL1-AS tumors were benign and contained smaller capillaries. Specimens of high HYAL1 producers were 99% free of tumor cells. This study shows that, depending on the concentration, HYAL1 functions as a tumor promoter and as a suppressor and provides a basis for anti-hyaluronidase and high-hyaluronidase treatments for cancer.

AB - Hyaluronidases degrade hyaluronic acid, which promotes metastasis. HYAL1 type hyaluronidase is an independent prognostic indicator of prostate cancer progression and a biomarker for bladder cancer. However, it is controversial whether hyaluronidase (e.g., HYAL1) functions as a tumor promoter or as a suppressor. We stably transfected prostate cancer cells, DU145 and PC-3 ML, with HYAL1-sense (HYAL1-S), HYAL1-antisense (HYAL1-AS), or vector DNA. HYAL1-AS transfectants were not generated for PC-3 ML because it expresses little HYAL1. HYAL1-S transfectants produced ≤42 milliunits (moderate overproducers) or ≥80 milliunits hyaluronidase activity (high producers). HYAL1-AS transfectants produced <10% hyaluronidase activity when compared with vector transfectants (18-24 milliunits). Both blocking HYAL1 expression and high HYAL1 production resulted in a 4- to 5-fold decrease in prostate cancer cell proliferation. HYAL1-AS transfectants had a G2-M block due to decreased cyclin B1, cdc25c, and cdc2/p34 expression and cdc2/p34 kinase activity. High HYAL1 producers had a 3-fold increase in apoptotic activity and mitochondrial depolarization when compared with vector transfectants and expressed activated proapoptotic protein WOX1. Blocking HYAL1 expression inhibited tumor growth by 4- to 7-fold, whereas high HYAL1 producing transfectants either did not form tumors (DU145) or grew 3.5-fold slower (PC-3 ML). Whereas vector and moderate HYAL1 producers generated muscle and blood vessel infiltrating tumors, HYAL1-AS tumors were benign and contained smaller capillaries. Specimens of high HYAL1 producers were 99% free of tumor cells. This study shows that, depending on the concentration, HYAL1 functions as a tumor promoter and as a suppressor and provides a basis for anti-hyaluronidase and high-hyaluronidase treatments for cancer.

UR - http://www.scopus.com/inward/record.url?scp=24744443035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24744443035&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-1022

DO - 10.1158/0008-5472.CAN-05-1022

M3 - Article

C2 - 16140946

AN - SCOPUS:24744443035

VL - 65

SP - 7782

EP - 7789

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 17

ER -